Fintech
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
New York, New York–(Newsfile Corp. – June 17, 2021) – PCG Digital — Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology “did not negate the known efficacy of those compounds.”
“This test is conducted as a pass/fail,” said Chris Bunka, CEO of Lexaria Bioscience. “We needed to know if DehydraTECHTM interferes in any way with the effects these drugs have on the virus. It doesn’t give us any direct score on “how well” it works or does not, just a yes-no. The next step is to move on to in vivo efficacy testing in animals and then eventually humans.”
That’s good news on two fronts for Lexaria. The first and most obvious is that DehydraTECHTM works with these important antivirals. The second is that it opens the door to an antiviral market projected to be worth USD$44 billion by 2026. The company is not limiting its scope in this area to only COVID-19 drugs. Several antivirals will be tested in the same manner.
Remdesivir, which is sold under the brand name Veklury, is a broad-spectrum antiviral that was originally developed to treat hepatitis C. It was approved and authorized for emergency use by the FDA as a therapeutic treatment for COVID-19 in 2020. Lexaria would like to emphasize that the use of DehydraTECHTM with Remdesivir does not create a “cure” for COVID-19.
Ebastine is an antihistamine that is administered orally. It’s used for treatment of allergic rhinitis and chronic idiopathic urticaria. In some countries it is also used for relief from mosquito bites or atopic dermatitis. It’s been in medical use since 1990 and is available in 10mg to 20mg tablets, fast-dissolving tablets, and as a pediatric syrup.
Remdesivir and Ebastine both face bioavailability challenges when administered orally, thus limiting their commercial potential. Lexaria hopes to change this with its technology.
This week, Lexaria announced it had measured circulating drug levels of DehydraTECH-enabled Remdesivir and Ebastine twice or even three times higher than concentration-matched controls without DehydraTECH. Mr. Bunka described the outcome as “the best results Lexaria has ever generated demonstrating our technology’s ability to more effectively deliver antiviral drugs when taken orally.”
Lexaria Has a Track Record of Success with DehydraTECHTM
Antivirals are not the only market where DehydraTECHTM has been proven to be effective. In 2018, Lexaria ran a human clinical trial on hypertension using DehydraTECHTM CBD. The results showed a 5% drop in blood pressure after just one 90mg dose. CBD administered using Lexaria’s patented dehydration process was shown to deliver 300%+ more CBD in under 30 minutes.
Those results were the first step into a $30 billion antihypertensive drug market. Phase I of human clinical trials on the drug, HYPER-H21-1, were completed ahead of schedule this month and the commencement of Phase II was announced this week. The primary objectives of the study are time series blood pressure and heart rate analysis.
Since 2016, DehydraTECHTM has been consistently proven effective in both CBD and nicotine bio-absorption. Lexaria has licensed the technology to multiple companies in those sectors and has plans to further evaluate DehydraTECHTM with antivirals, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, human hormones, and vitamins.
The antiviral results, combined with significant progress in the antihypertensive space, increases the likelihood of a Big Pharma partnership for Lexaria. Remdesivir is owned by Gilead Sciences, a company known for acquisitions and partnerships with firms developing cutting edge pharmaceutical technology. Is there synergy there? Time will tell.
Disclaimer
This communication was produced by PCG Digital LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG is compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information.
The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall “PCG” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PCG”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PCG” unless you can afford to lose your entire investment. We urge investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.
Contact: [email protected]
As we close out 2024, the fintech industry continues to deliver headlines that underscore its dynamism and innovation. From IPO aspirations to groundbreaking regulatory milestones, today’s updates highlight the transformative power of fintech partnerships, regulatory evolution, and disruptive technologies. Here’s what you need to know.
Chime’s Quiet Step Toward Public Markets
Chime, the U.S.-based financial technology startup best known for its digital banking services, has taken a significant step by filing confidential paperwork for an initial public offering (IPO). As one of the most valuable private fintechs in the U.S., Chime’s move could potentially signal a renewed appetite for fintech IPOs in a market that has been cautious following fluctuating valuations across the tech sector.
With a valuation that reportedly exceeded $25 billion in its last funding round, Chime’s IPO could set a new benchmark for the industry. Observers note that its strong customer base and revenue growth may make it an appealing choice for investors seeking to capitalize on the digital banking boom. However, the timing and success of the IPO will depend on broader market conditions and the regulatory landscape.
Source: Bloomberg
ZBD’s Pioneering Achievement: EU MiCA License Approval
ZBD, a fintech company specializing in Bitcoin Lightning network solutions, has made history by becoming the first to secure an EU MiCA (Markets in Crypto-Assets Regulation) license. This landmark approval by the Dutch regulator positions ZBD at the forefront of compliant crypto-fintech operations in Europe.
MiCA, which aims to harmonize the regulatory framework for crypto-assets across the EU, has been a focal point for industry players aiming to establish legitimacy and expand their offerings. ZBD’s achievement not only validates its operational rigor but also sets a precedent for other fintech firms navigating the evolving regulatory landscape.
Industry insiders view this as a strategic advantage for ZBD as it broadens its footprint in Europe. By leveraging its regulatory approval, the company can accelerate its product deployment and establish trust with institutional and retail users alike.
Source: Coindesk, PR Newswire
The Fintech-Credit Union Synergy: A Blueprint for Innovation
The convergence of fintechs and credit unions continues to reshape the financial services ecosystem. Collaborative initiatives, such as the one highlighted in the recent partnership between fintech innovators and credit unions, are proving to be a potent force in delivering tailored financial solutions.
This “dream team” approach allows credit unions to leverage fintech’s technological expertise while maintaining their community-focused ethos. Key areas of collaboration include digital payments, personalized financial management tools, and enhanced loan processing capabilities. These partnerships not only enhance member engagement but also enable credit unions to remain competitive in an increasingly digital-first financial environment.
Industry analysts emphasize that such collaborations underscore a broader trend of traditional financial institutions embracing fintech-driven solutions to bridge service gaps and foster innovation.
Source: PYMNTS
Tackling Student Loan Debt: A Fintech’s Mission
Student loan debt remains a pressing issue for millions of Americans, and a Rochester-based fintech aims to offer relief through its cloud-based platform. This innovative solution is designed to simplify loan management and provide borrowers with actionable insights to reduce their debt burden.
The platform’s features include repayment optimization tools, personalized financial education, and seamless integration with loan servicers. By addressing the complexities of student loan management, this fintech is empowering borrowers to make informed decisions and achieve financial stability.
As the student loan crisis continues to evolve, solutions like this highlight the critical role fintech can play in addressing systemic financial challenges while fostering financial literacy and inclusion.
Source: RBJ
Industry Implications and Takeaways
Today’s updates underscore several key themes shaping the fintech landscape:
- Regulatory Milestones: ZBD’s MiCA license approval exemplifies the importance of regulatory compliance in unlocking growth opportunities.
- Strategic Partnerships: The collaboration between fintechs and credit unions demonstrates the value of combining technological innovation with traditional financial models to drive customer-centric solutions.
- Market Opportunities: Chime’s IPO move reflects a potential revival in fintech public offerings, signaling confidence in the sector’s long-term prospects.
- Social Impact: Fintech’s ability to tackle systemic issues, such as student loan debt, showcases its role as a force for positive change.
The post Fintech Pulse: Your Daily Industry Brief (Chime, ZBD, MiCA) appeared first on News, Events, Advertising Options.
Leading global payments platform SPAYZ.io has confirmed it will be attending iFX EXPO Dubai 2025 on 14 to 16 January. Exhibiting at Stand 64 at Trade Centre Dubai, SPAYZ.io’s team of professionals will be on hand providing live demonstrations of its renowned payment services for payment providers. Attendees will also receive exclusive insight into SPAYZ.io’s plans for 2025 alongside early early access to its upcoming plans for the new year.
SPAYZ.io delivers a host of payment solutions that leverage the latest technological innovations and open access to the fastest growing emerging markets across Africa, Europe and Asia. Over the past year, there has been huge demand for its Open Banking and local payment method services, alongside bank transfers, mass payouts, online banking and e-wallets.
Yana Thakurta, Head of Business Development at SPAYZ.io commented: “We look forward to once again participating at iFX Dubai to expand our network of partners and clients. It’s a fantastic way to kick off the year, connecting with thousands of industry leaders from FOREX platforms to trading companies, and everything in between.
“Our key goal for iFX Dubai EXPO 2025 is to expand our portfolio of solutions and geographies. We’re using this as an opportunity to partner with like-minded entities who share our ambition to provide payment solutions that are truly global.”
Come meet SPAYZ.io’s team at the Trade Centre Dubai at Stand 64. You can also book a meeting slot with a member of a team.
The post SPAYZ.io prepares for iFX EXPO Dubai 2025 appeared first on News, Events, Advertising Options.
Airtm, the most connected digital dollar account in the world, is proud to announce the addition of two distinguished industry leaders to its Board of Directors: Rafael de la Vega, Global SVP of Partnerships at Auctane, and Shivani Siroya, CEO & Founder of Tala. These appointments reflect Airtm’s commitment to innovation and financial inclusion as the company enters its next phase of growth.
“We are thrilled to welcome Rafael and Shivani to Airtm’s Board of Directors,” said Ruben Galindo Steckel, Co-founder and CEO of Airtm. “Their unique perspectives and proven track records will be invaluable as we continue scaling our platform to empower individuals and businesses in emerging markets. Together, we’ll push the boundaries of financial inclusion and innovation to create a more connected and equitable global economy. Rafael and Shivani bring a wealth of experience and strategic insight that will strengthen Airtm’s mission to connect emerging economies with the global market.”
Rafael de la Vega, a seasoned leader in fintech global partnerships and technology innovation, is currently the Global SVP of Partnerships at Auctane. With a proven track record of delivering scalable, impactful solutions at the intersection of fintech, innovation, and commerce, Rafael’s expertise will be pivotal as Airtm continues to grow. “Airtm has built a platform that breaks down barriers and opens up opportunities for people in emerging economies to connect to global markets. I am excited to contribute to its growth and help further its mission of fostering financial inclusion on a global scale,” said Rafael.
Shivani Siroya, CEO and Founder of Tala, is a pioneer in financial technology, renowned for empowering underserved communities through access to credit and essential financial tools. Her leadership in leveraging data-driven innovation aligns seamlessly with Airtm’s vision of creating more equitable financial opportunities. “Empowering underserved communities has always been at the core of my work, and Airtm’s mission resonates deeply with me. I’m thrilled to join the Board and work alongside such a dynamic team to expand access to financial tools that truly make a difference in people’s lives,” said Shivani.
The post Airtm Enhances Its Board of Directors with Two Strategic Appointments appeared first on News, Events, Advertising Options.
-
Fintech PR4 days agoGCL Energy Technology and Ant Digital Technologies Launch First Blockchain-Based RWA Project in Photovoltaic Industry
-
Fintech PR3 days ago2025 Will See Increased QR Code Payments but Payment Card IC ASPs Will Not Return to Pre-Covid Levels
-
Fintech PR3 days agoBybit Champions Web3 Innovation and Strengthens Ties with Asia’s Crypto Community at Taipei Blockchain Week
-
Fintech PR4 days agoCKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
-
Fintech PR4 days agoH.I.G. Realty Announces Strategic Partnership with Queen Mary BioEnterprises Innovation Centre in London
-
Fintech PR4 days agoDesigning for the future: SM’s vision through an architect’s lens
-
Fintech PR4 days agoAIMA Technology Welcomes Top U.S. Dealers to Shape the Future Together
-
Fintech PR4 days agoFXGiants Online Trading Platform Launches Bonus Initiative to Reward Traders